What is Qubit Pharmaceuticals?
Qubit Pharmaceuticals is a pioneering drug discovery firm leveraging advanced physics-driven methodologies. The company employs sophisticated simulation software and AI-enhanced medicinal chemistry to engineer novel drug candidates. Its core competency lies in developing innovative modes of action against challenging therapeutic targets. Qubit Pharmaceuticals designs its drug candidates at an atomic level, optimizing for enhanced efficiency, specificity, and a favorable safety profile, all achieved at an unprecedented pace. This physics-driven approach positions the company at the forefront of next-generation pharmaceutical development.
How much funding has Qubit Pharmaceuticals raised?
Qubit Pharmaceuticals has raised a total of $16.9M across 1 funding round:
Angel/Seed
$16.9M
Angel/Seed (2022): $16.9M with participation from XAnge, Omnes Capital, and Quantonation
Key Investors in Qubit Pharmaceuticals
XAnge
XAnge is a European early-stage venture capital firm with a strong track record in supporting Seed to Series B startups. They focus on providing capital and expertise to visionary founders, with a significant history of successful exits and unicorn creation.
Omnes Capital
Omnes Capital is a leading European private equity firm with a focus on energy transition and deeptech innovation. They manage substantial assets and partner with entrepreneurs to drive growth in sustainable sectors.
Quantonation
Quantonation is a global early-stage venture capital fund specializing in novel technologies rooted in physics and computing. They invest in areas like quantum technologies, aiming to transform cutting-edge scientific advancements into commercially viable products.
What's next for Qubit Pharmaceuticals?
With the recent major strategic investment, Qubit Pharmaceuticals is poised for accelerated growth and the expansion of its drug development pipeline. The substantial capital infusion is expected to fuel further research and development, enabling the company to advance its novel drug candidates through preclinical and clinical stages. This funding will likely support the scaling of its AI and simulation platforms, enhancing its capacity to tackle complex diseases. The strategic nature of this investment suggests a focus on forging key partnerships and potentially preparing for future commercialization efforts, solidifying Qubit Pharmaceuticals' trajectory in the competitive pharmaceutical sector.
See full Qubit Pharmaceuticals company page
